Concepts (275)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinsonian Disorders | 10 | 2023 | 225 | 4.650 |
Why?
|
| Stroke | 20 | 2023 | 261 | 3.960 |
Why?
|
| Brain | 16 | 2023 | 1649 | 3.420 |
Why?
|
| Alzheimer Disease | 13 | 2023 | 2109 | 3.100 |
Why?
|
| Cognitive Dysfunction | 9 | 2023 | 1061 | 2.530 |
Why?
|
| Intracranial Arteriosclerosis | 3 | 2022 | 54 | 2.210 |
Why?
|
| Cerebrovascular Disorders | 4 | 2023 | 133 | 1.780 |
Why?
|
| Aged | 43 | 2023 | 8997 | 1.710 |
Why?
|
| Aged, 80 and over | 28 | 2023 | 4777 | 1.710 |
Why?
|
| Brain Ischemia | 6 | 2020 | 63 | 1.580 |
Why?
|
| Female | 56 | 2023 | 15212 | 1.540 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 55 | 1.500 |
Why?
|
| Male | 54 | 2023 | 14772 | 1.480 |
Why?
|
| Humans | 69 | 2023 | 27072 | 1.380 |
Why?
|
| Dementia | 4 | 2023 | 560 | 1.330 |
Why?
|
| Apolipoprotein E4 | 3 | 2020 | 263 | 1.240 |
Why?
|
| Hypertension | 8 | 2023 | 192 | 1.110 |
Why?
|
| Arteriolosclerosis | 3 | 2023 | 78 | 1.100 |
Why?
|
| Risk Factors | 24 | 2023 | 2302 | 1.070 |
Why?
|
| Atherosclerosis | 3 | 2023 | 53 | 1.060 |
Why?
|
| Neuropsychological Tests | 6 | 2023 | 1196 | 1.050 |
Why?
|
| Aging | 11 | 2023 | 1544 | 1.050 |
Why?
|
| Dementia, Vascular | 2 | 2016 | 46 | 1.020 |
Why?
|
| Disease Progression | 5 | 2021 | 673 | 0.990 |
Why?
|
| tau Proteins | 4 | 2023 | 232 | 0.970 |
Why?
|
| Incidence | 15 | 2022 | 759 | 0.970 |
Why?
|
| Independent Living | 4 | 2023 | 322 | 0.920 |
Why?
|
| TDP-43 Proteinopathies | 2 | 2023 | 112 | 0.910 |
Why?
|
| Stroke Rehabilitation | 2 | 2019 | 24 | 0.900 |
Why?
|
| Cardiovascular Diseases | 10 | 2018 | 321 | 0.900 |
Why?
|
| Limbic Encephalitis | 1 | 2023 | 13 | 0.840 |
Why?
|
| Amyloid beta-Peptides | 4 | 2023 | 324 | 0.840 |
Why?
|
| Motor Disorders | 1 | 2023 | 23 | 0.830 |
Why?
|
| Disabled Persons | 2 | 2023 | 122 | 0.810 |
Why?
|
| Longitudinal Studies | 13 | 2023 | 1368 | 0.790 |
Why?
|
| Iran | 18 | 2021 | 29 | 0.770 |
Why?
|
| Executive Function | 2 | 2015 | 111 | 0.760 |
Why?
|
| Prefrontal Cortex | 3 | 2023 | 136 | 0.730 |
Why?
|
| Exercise | 4 | 2023 | 450 | 0.710 |
Why?
|
| Cerebral Hemorrhage | 7 | 2023 | 96 | 0.700 |
Why?
|
| Transcranial Magnetic Stimulation | 2 | 2021 | 17 | 0.690 |
Why?
|
| Health Status | 2 | 2021 | 218 | 0.690 |
Why?
|
| Mobility Limitation | 1 | 2021 | 94 | 0.680 |
Why?
|
| White Matter | 1 | 2021 | 134 | 0.670 |
Why?
|
| Mental Health | 1 | 2021 | 108 | 0.660 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2021 | 111 | 0.660 |
Why?
|
| Child Development | 1 | 2020 | 73 | 0.650 |
Why?
|
| Vision, Ocular | 1 | 2019 | 1 | 0.650 |
Why?
|
| Beta Rhythm | 1 | 2019 | 3 | 0.650 |
Why?
|
| Eyeglasses | 1 | 2019 | 3 | 0.650 |
Why?
|
| Agnosia | 1 | 2019 | 9 | 0.650 |
Why?
|
| Visual Perception | 1 | 2019 | 30 | 0.650 |
Why?
|
| Blood Pressure | 2 | 2020 | 195 | 0.640 |
Why?
|
| Cohort Studies | 14 | 2022 | 1890 | 0.640 |
Why?
|
| Brain Infarction | 1 | 2020 | 75 | 0.630 |
Why?
|
| Motor Activity | 3 | 2019 | 323 | 0.630 |
Why?
|
| Gait | 1 | 2023 | 412 | 0.620 |
Why?
|
| Cognition | 4 | 2023 | 1339 | 0.600 |
Why?
|
| Sex Characteristics | 1 | 2018 | 116 | 0.570 |
Why?
|
| Transcranial Direct Current Stimulation | 1 | 2017 | 9 | 0.560 |
Why?
|
| Upper Extremity | 1 | 2017 | 64 | 0.540 |
Why?
|
| Age Factors | 7 | 2021 | 766 | 0.530 |
Why?
|
| Middle Aged | 29 | 2023 | 8923 | 0.520 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2015 | 27 | 0.500 |
Why?
|
| Autopsy | 4 | 2021 | 344 | 0.500 |
Why?
|
| Aspirin | 1 | 2015 | 83 | 0.470 |
Why?
|
| Triglycerides | 3 | 2022 | 61 | 0.460 |
Why?
|
| Parkinson Disease | 4 | 2023 | 670 | 0.440 |
Why?
|
| Case-Control Studies | 11 | 2023 | 587 | 0.420 |
Why?
|
| Metabolic Syndrome | 4 | 2018 | 58 | 0.420 |
Why?
|
| Receptors, Estrogen | 2 | 2023 | 65 | 0.410 |
Why?
|
| Canada | 4 | 2015 | 47 | 0.350 |
Why?
|
| Obesity | 4 | 2019 | 311 | 0.330 |
Why?
|
| Adult | 18 | 2023 | 7831 | 0.330 |
Why?
|
| DNA-Binding Proteins | 2 | 2023 | 276 | 0.320 |
Why?
|
| Prospective Studies | 9 | 2023 | 1778 | 0.320 |
Why?
|
| Time Factors | 4 | 2019 | 1433 | 0.310 |
Why?
|
| Follow-Up Studies | 8 | 2020 | 1792 | 0.310 |
Why?
|
| Cognition Disorders | 3 | 2016 | 985 | 0.300 |
Why?
|
| Waist Circumference | 4 | 2019 | 35 | 0.300 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 381 | 0.280 |
Why?
|
| Recovery of Function | 2 | 2019 | 295 | 0.270 |
Why?
|
| Disability Evaluation | 2 | 2019 | 264 | 0.270 |
Why?
|
| Treatment Outcome | 6 | 2021 | 3485 | 0.250 |
Why?
|
| Language | 1 | 2006 | 63 | 0.250 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 891 | 0.240 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 347 | 0.240 |
Why?
|
| Neurofibrillary Tangles | 2 | 2023 | 193 | 0.240 |
Why?
|
| Hospitalization | 1 | 2007 | 300 | 0.240 |
Why?
|
| Activities of Daily Living | 2 | 2023 | 595 | 0.240 |
Why?
|
| Waist-Hip Ratio | 5 | 2019 | 13 | 0.240 |
Why?
|
| Surveys and Questionnaires | 3 | 2019 | 1144 | 0.240 |
Why?
|
| Risk Assessment | 4 | 2021 | 624 | 0.220 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2023 | 19 | 0.220 |
Why?
|
| Binge Drinking | 1 | 2023 | 9 | 0.210 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2023 | 26 | 0.210 |
Why?
|
| RNA | 1 | 2023 | 37 | 0.210 |
Why?
|
| Cerebrum | 1 | 2023 | 9 | 0.200 |
Why?
|
| Smoking | 3 | 2020 | 176 | 0.200 |
Why?
|
| Opium | 1 | 2022 | 1 | 0.200 |
Why?
|
| Hand Strength | 1 | 2023 | 58 | 0.200 |
Why?
|
| Cholesterol | 1 | 2022 | 64 | 0.200 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2023 | 64 | 0.200 |
Why?
|
| Spinal Cord | 1 | 2022 | 84 | 0.190 |
Why?
|
| Spastic Paraplegia, Hereditary | 1 | 2021 | 1 | 0.190 |
Why?
|
| Motor Cortex | 1 | 2021 | 17 | 0.190 |
Why?
|
| Migraine Disorders | 1 | 2021 | 19 | 0.190 |
Why?
|
| Life Style | 2 | 2020 | 186 | 0.180 |
Why?
|
| Diabetes Mellitus | 2 | 2020 | 127 | 0.180 |
Why?
|
| Ontario | 1 | 2021 | 16 | 0.180 |
Why?
|
| Potassium | 1 | 2021 | 62 | 0.180 |
Why?
|
| Sodium | 1 | 2021 | 58 | 0.180 |
Why?
|
| Movement Disorders | 1 | 2021 | 66 | 0.180 |
Why?
|
| Nerve Block | 1 | 2021 | 66 | 0.180 |
Why?
|
| Sex Factors | 2 | 2020 | 464 | 0.170 |
Why?
|
| Peptides | 1 | 2021 | 102 | 0.170 |
Why?
|
| Walking | 1 | 2023 | 253 | 0.170 |
Why?
|
| Biomarkers | 2 | 2020 | 562 | 0.170 |
Why?
|
| Psychomotor Performance | 1 | 2021 | 205 | 0.170 |
Why?
|
| Residence Characteristics | 2 | 2012 | 214 | 0.160 |
Why?
|
| Functional Laterality | 1 | 2019 | 59 | 0.160 |
Why?
|
| Linear Models | 1 | 2020 | 247 | 0.160 |
Why?
|
| Depression | 1 | 2023 | 444 | 0.160 |
Why?
|
| Apolipoproteins E | 1 | 2020 | 251 | 0.160 |
Why?
|
| Noncommunicable Diseases | 1 | 2018 | 2 | 0.160 |
Why?
|
| Heredity | 1 | 2018 | 7 | 0.160 |
Why?
|
| Pedigree | 1 | 2018 | 65 | 0.150 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 300 | 0.150 |
Why?
|
| Glycogen Storage Disease Type III | 1 | 2018 | 1 | 0.150 |
Why?
|
| Chi-Square Distribution | 1 | 2018 | 139 | 0.150 |
Why?
|
| Glycogen | 1 | 2018 | 14 | 0.150 |
Why?
|
| ROC Curve | 4 | 2022 | 141 | 0.150 |
Why?
|
| Pilot Projects | 1 | 2019 | 420 | 0.150 |
Why?
|
| Milk | 1 | 2017 | 14 | 0.140 |
Why?
|
| Nonlinear Dynamics | 1 | 2017 | 12 | 0.140 |
Why?
|
| CADASIL | 1 | 2017 | 1 | 0.140 |
Why?
|
| Research Design | 1 | 2018 | 185 | 0.140 |
Why?
|
| Menopause | 1 | 2018 | 101 | 0.140 |
Why?
|
| Genotype | 1 | 2018 | 346 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 111 | 0.140 |
Why?
|
| alpha-Synuclein | 1 | 2018 | 130 | 0.140 |
Why?
|
| Feasibility Studies | 1 | 2017 | 220 | 0.130 |
Why?
|
| Vasodilation | 1 | 2016 | 5 | 0.130 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2016 | 6 | 0.130 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2016 | 5 | 0.130 |
Why?
|
| Chicago | 1 | 2020 | 949 | 0.130 |
Why?
|
| Mutation | 1 | 2018 | 348 | 0.130 |
Why?
|
| Methamphetamine | 1 | 2016 | 22 | 0.130 |
Why?
|
| Child | 1 | 2020 | 1295 | 0.130 |
Why?
|
| Central Nervous System Stimulants | 1 | 2016 | 41 | 0.130 |
Why?
|
| Neuropathology | 1 | 2016 | 81 | 0.130 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 474 | 0.130 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 40 | 0.130 |
Why?
|
| Tropanes | 1 | 2015 | 1 | 0.130 |
Why?
|
| Organotechnetium Compounds | 1 | 2015 | 7 | 0.130 |
Why?
|
| Cholesterol, HDL | 1 | 2015 | 26 | 0.120 |
Why?
|
| Blood Chemical Analysis | 1 | 2015 | 17 | 0.120 |
Why?
|
| Myocardial Ischemia | 1 | 2016 | 44 | 0.120 |
Why?
|
| Prediabetic State | 1 | 2014 | 3 | 0.120 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2015 | 79 | 0.120 |
Why?
|
| Heart Rate | 1 | 2014 | 114 | 0.110 |
Why?
|
| Incidental Findings | 1 | 2014 | 13 | 0.110 |
Why?
|
| Body Mass Index | 3 | 2023 | 458 | 0.100 |
Why?
|
| Memory | 1 | 2015 | 297 | 0.100 |
Why?
|
| Interviews as Topic | 2 | 2019 | 132 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 167 | 0.100 |
Why?
|
| Rural Population | 1 | 2012 | 22 | 0.100 |
Why?
|
| Quality of Life | 1 | 2016 | 629 | 0.090 |
Why?
|
| Urban Population | 1 | 2012 | 153 | 0.090 |
Why?
|
| Phenotype | 2 | 2023 | 312 | 0.080 |
Why?
|
| Alcohol Drinking | 2 | 2022 | 75 | 0.080 |
Why?
|
| Logistic Models | 1 | 2010 | 395 | 0.080 |
Why?
|
| Efferent Pathways | 1 | 2008 | 1 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 676 | 0.080 |
Why?
|
| Neural Conduction | 1 | 2008 | 11 | 0.070 |
Why?
|
| Action Potentials | 1 | 2008 | 86 | 0.070 |
Why?
|
| Age Distribution | 1 | 2007 | 85 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2012 | 879 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2022 | 3538 | 0.070 |
Why?
|
| Skin | 1 | 2008 | 123 | 0.070 |
Why?
|
| Comorbidity | 2 | 2021 | 481 | 0.070 |
Why?
|
| Middle East | 2 | 2017 | 3 | 0.070 |
Why?
|
| Developing Countries | 2 | 2018 | 12 | 0.070 |
Why?
|
| Diabetes Complications | 2 | 2017 | 56 | 0.070 |
Why?
|
| Evidence-Based Medicine | 2 | 2018 | 161 | 0.070 |
Why?
|
| Europe | 2 | 2016 | 58 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2017 | 270 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 216 | 0.060 |
Why?
|
| Prognosis | 2 | 2018 | 785 | 0.060 |
Why?
|
| Angina, Unstable | 2 | 2014 | 9 | 0.060 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2014 | 12 | 0.050 |
Why?
|
| Prevalence | 2 | 2016 | 443 | 0.050 |
Why?
|
| Infarction | 1 | 2023 | 29 | 0.050 |
Why?
|
| Adaptor Protein Complex 1 | 1 | 2023 | 7 | 0.050 |
Why?
|
| Adaptor Protein Complex beta Subunits | 1 | 2023 | 7 | 0.050 |
Why?
|
| Olfactory Bulb | 1 | 2023 | 17 | 0.050 |
Why?
|
| Proteome | 1 | 2023 | 41 | 0.050 |
Why?
|
| Myocardial Infarction | 2 | 2014 | 133 | 0.050 |
Why?
|
| Health Surveys | 2 | 2013 | 86 | 0.050 |
Why?
|
| Muscle Spasticity | 1 | 2021 | 5 | 0.050 |
Why?
|
| Triamcinolone | 1 | 2021 | 6 | 0.050 |
Why?
|
| Lewy Bodies | 1 | 2023 | 192 | 0.050 |
Why?
|
| Lidocaine | 1 | 2021 | 23 | 0.050 |
Why?
|
| Lower Extremity | 1 | 2021 | 38 | 0.050 |
Why?
|
| Headache | 1 | 2021 | 35 | 0.050 |
Why?
|
| Potassium, Dietary | 1 | 2021 | 1 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2022 | 117 | 0.050 |
Why?
|
| Sodium, Dietary | 1 | 2021 | 6 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 1 | 2021 | 39 | 0.050 |
Why?
|
| Causality | 1 | 2021 | 56 | 0.050 |
Why?
|
| Young Adult | 2 | 2018 | 1994 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2021 | 260 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2022 | 235 | 0.040 |
Why?
|
| Sleep | 1 | 2023 | 328 | 0.040 |
Why?
|
| Waist-Height Ratio | 1 | 2019 | 5 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 2019 | 27 | 0.040 |
Why?
|
| Blood Pressure Determination | 1 | 2019 | 14 | 0.040 |
Why?
|
| Anthropometry | 1 | 2019 | 34 | 0.040 |
Why?
|
| Adiposity | 1 | 2019 | 43 | 0.040 |
Why?
|
| Gene-Environment Interaction | 1 | 2018 | 18 | 0.040 |
Why?
|
| Physical Examination | 1 | 2019 | 116 | 0.040 |
Why?
|
| Glycogen Debranching Enzyme System | 1 | 2018 | 1 | 0.040 |
Why?
|
| Developed Countries | 1 | 2018 | 3 | 0.040 |
Why?
|
| Mediterranean Region | 1 | 2017 | 1 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 83 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 38 | 0.040 |
Why?
|
| Age of Onset | 1 | 2018 | 94 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2018 | 257 | 0.040 |
Why?
|
| Poverty | 1 | 2018 | 96 | 0.030 |
Why?
|
| Microvessels | 1 | 2017 | 14 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 112 | 0.030 |
Why?
|
| Liver Transplantation | 1 | 2018 | 89 | 0.030 |
Why?
|
| Nitroglycerin | 1 | 2016 | 1 | 0.030 |
Why?
|
| Carotid Artery, Common | 1 | 2016 | 3 | 0.030 |
Why?
|
| Overweight | 1 | 2017 | 72 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2017 | 260 | 0.030 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2016 | 18 | 0.030 |
Why?
|
| Apolipoproteins B | 1 | 2016 | 2 | 0.030 |
Why?
|
| Apolipoprotein A-I | 1 | 2016 | 2 | 0.030 |
Why?
|
| Asia | 1 | 2016 | 10 | 0.030 |
Why?
|
| Africa | 1 | 2016 | 10 | 0.030 |
Why?
|
| International Cooperation | 1 | 2016 | 15 | 0.030 |
Why?
|
| Vasodilator Agents | 1 | 2016 | 31 | 0.030 |
Why?
|
| Australia | 1 | 2016 | 40 | 0.030 |
Why?
|
| China | 1 | 2016 | 46 | 0.030 |
Why?
|
| Obesity, Abdominal | 1 | 2016 | 19 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 329 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 204 | 0.030 |
Why?
|
| Demography | 1 | 2016 | 72 | 0.030 |
Why?
|
| Reference Standards | 1 | 2015 | 23 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2016 | 85 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2016 | 75 | 0.030 |
Why?
|
| Health Behavior | 1 | 2016 | 159 | 0.030 |
Why?
|
| Self Report | 1 | 2016 | 223 | 0.030 |
Why?
|
| United States | 1 | 2021 | 2035 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 302 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2018 | 383 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 348 | 0.030 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 131 | 0.030 |
Why?
|
| Rural Health | 1 | 2013 | 7 | 0.030 |
Why?
|
| Urban Health | 1 | 2013 | 22 | 0.030 |
Why?
|
| Diet | 1 | 2014 | 220 | 0.030 |
Why?
|
| Adolescent | 1 | 2018 | 2172 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 2012 | 18 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 94 | 0.020 |
Why?
|
| Public Health | 1 | 2012 | 69 | 0.020 |
Why?
|
| Reference Values | 1 | 2012 | 186 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2011 | 127 | 0.020 |
Why?
|
| Survival Rate | 1 | 2012 | 342 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 164 | 0.020 |
Why?
|
| Animals | 1 | 2017 | 3642 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2008 | 51 | 0.020 |
Why?
|
| Electrophysiology | 1 | 2008 | 99 | 0.020 |
Why?
|
| Hand | 1 | 2008 | 39 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2008 | 227 | 0.020 |
Why?
|